Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.61 |
| ▸ | NTRK2 known ✓ | Q16620 | 2/20 | 0.56 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 0.49 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.47 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.46 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.46 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.46 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.46 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.46 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.46 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.95 |
| ▸ | CA9 | Q16790 | 1/20 | 0.95 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29374879 | 0.98 | CA12 (0.91) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL29355184 | 0.98 | CA12 (1.00) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL14896 | 0.98 | CA12 (1.00) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL4818277 | 0.98 | CA12 (1.00) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL8213864 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 | |
| Water SCHEMBL19462706 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL11354047 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 | |
| Water SCHEMBL19462703 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 | |
| SCHEMBL8213866 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 | |
| Water SCHEMBL19462837 | 0.95 | CA12 (0.95) | CA12CA9PARP1PDPK1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3582779-B1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-111377925-B | Purine derivatives, preparation method thereof and application thereof in medicines | 四川科伦博泰生物医药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-110446495-B | Delta opioid receptor modulating compounds containing 7-membered aza heterocycles and methods of use and preparation thereof | 特维娜有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3582783-B1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220348588-A1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114773318-A | Delta opioid receptor modulating compounds containing six-membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-101842366-A | Azacyclylisoquinolinone and azacyclylisoindolone derivatives as histamine-3 antagonists | WYETH CORP | 2010-09-22 | — | — | CN | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
| EP-0886637-B9 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0886637-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-0904262-B1 | CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-0954313-A4 | METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-0954313-A1 | METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998027979-A1 | HETEROCYCLIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998003174-A1 | METHOD FOR TREATING TUMORS HAVING HIGH LDL REQUIREMENTS EMPLOYING MTP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| US-4490527-A | Benzo-fused heterocyclic anti-ulcer agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | PARP1 1837/4885NTRK2 752/4885KDR 2222/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | PARP1 1804/4885NTRK2 794/4885KDR 2377/4885 |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | PARP1 1837/4885NTRK2 752/4885KDR 2222/4885 |
| US-20220348588-A1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | PARP1 1804/4885NTRK2 794/4885KDR 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.